Literature DB >> 33878313

Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.

Chao Guo1, Shuhuang Zhou1, Weimin Yi1, Pingzhou Yang1, Ou Li1, Jianming Liu1, Chuang Peng2.   

Abstract

BACKGROUNDS/AIMS: Hepatocellular carcinoma is recognized as the most common subtype of hepatic cancer. Muskelin 1 antisense RNA (MKLN1-AS) shows prognostic value in hepatitis B virus-hepatocellular carcinoma. The aim of this study is to investigate the detailed biological role of MKLN1-AS and Yes-associated transcriptional regulator 1 (YAP1)-related mechanisms.
METHODS: Based on online databases (GEPIA, TCGA, and GEO), the expression of MKLN1-AS and YAP1 in patients with hepatocellular carcinoma was analyzed. The IntaRNA algorithm was used to predict complementary sites between MKLN1-AS and YAP1 mRNA. Hepatocellular carcinoma tumor tissues and cells were collected for the quantification of MKLN1-AS and YAP1. FISH was performed to explore the location of MKLN1-AS in cells. The effects of MKLN1-AS and YAP1 on proliferation, migration and invasionof hepatocellular carcinoma were determined in vitro and in vivo. Actinomycin D and RNA immunoprecipitation were resorted to confirm the regulatory role of MKLN1-AS in YAP1 expression.
RESULTS: The up-regulation of MKLN1-AS contributed to the poor prognosis of patients with hepatocellular carcinoma. MKLN1-AS and YAP1 were overexpressed in hepatocellular carcinoma tissues and cells. MKLN1-AS positively modulated YAP1 expression through targeting and stabilizing YAP1 mRNA.MKLN1-AS was predominantly located in the cytoplasm of the cells. MKLN1-AS intensified proliferation, migration and invasion of hepatocellular carcinoma cells via YAP1. MKLN1-AS also caused hepatocarcinogenesis through inducing YAP1 expression in vivo.
CONCLUSIONS: MKLN1-AS overexpression enhances the stability of YAP1 mRNA, which is necessary for the oncogenic activity of MKLN1-AS. MKLN1-AS can be utilized in the diagnosis and prognosis of hepatocellular carcinoma as an upstream factor of YAP1.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Hepatocarcinogenesis; Hepatocellular carcinoma; MKLN1-AS; YAP1

Year:  2021        PMID: 33878313     DOI: 10.1016/j.yexmp.2021.104638

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  9 in total

1.  Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients.

Authors:  Xianbin Wu; Zhejun Deng; Xiaomin Liao; Xianxian Ruan; Nanfang Qu; Lixing Pang; Xiaoyan Shi; Shanyu Qin; Haixing Jiang
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment.

Authors:  Xijun Chen; Qing Ye; Zhigao Chen; Qian Lin; Wen Chen; Chengrong Xie; Xiaomin Wang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1.

Authors:  Guozheng Pan; Jian Zhang; Faping You; Tao Cui; Peng Luo; Shuling Wang; Xiaomei Li; Qingzhong Yuan
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

4.  Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.

Authors:  Xin Yang; Minhui Mei; Jingze Yang; Jinlu Guo; Fan Du; Shi Liu
Journal:  Aging (Albany NY)       Date:  2022-05-12       Impact factor: 5.955

5.  Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma.

Authors:  Xinyu Li; Shuqiao Zhang; Shijun Zhang; Weihong Kuang; Chunzhi Tang
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

6.  A Noval Established Cuproptosis-Associated LncRNA Signature for Prognosis Prediction in Primary Hepatic Carcinoma.

Authors:  Lan Luo; Xiaoyan Hu; Aoshuang Huang; Xiaofang Liu; Lingyun Wang; Tao Du; Lei Liu; Ming Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-15       Impact factor: 2.650

7.  Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature.

Authors:  Ze Zhang; Jin Shang; Bingyang Hu; Huizhong Shi; Yinbiao Cao; Junfeng Li; Tianyu Jiao; Wenwen Zhang; Shichun Lu
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

8.  Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing.

Authors:  Bingxian Bian; Li Li; Xing Ke; Hui Chen; Yi Liu; Naisheng Zheng; Yingxia Zheng; Yanhui Ma; Yunlan Zhou; Junyao Yang; Lanshu Xiao; Lisong Shen
Journal:  Front Oncol       Date:  2022-09-01       Impact factor: 5.738

9.  Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.

Authors:  Xiao-Li Zhu; Qing Li; Jie Shen; Li Shan; Er-Dong Zuo; Xu Cheng
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.